Lung cancer subtypes generate unique immune responses

Journal of Immunology

Volumn 197, Issue 11, 2016, Pages 4493-4503

  Busch, Stephanie E ^a   Hanke, Mark L ^a   Kargl, Julia ^a,b   Metz, Heather E ^a   MacPherson, David ^a   McGarry Houghton, A ^a,c  

^a USA   (United States)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; INTERLEUKIN 17; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CANCER MODEL; CANCER TISSUE; CD8+ T LYMPHOCYTE; CELL COMPOSITION; CELL MIGRATION; CELLS BY BODY ANATOMY; CONTROLLED STUDY; CYTOKINE PRODUCTION; EGFR GENE; FEMALE; GENE MUTATION; GENETIC DIFFERENCE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; LEUKOCYTE COUNT; LUNG ADENOCARCINOMA; MOUSE; MUTANT; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SMALL CELL LUNG CANCER; TISSUE MICROARRAY; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; ADENOCARCINOMA; ANIMAL; GENETICS; IMMUNOLOGY; LUNG TUMOR; MUTATION; PATHOLOGY; TRANSGENIC MOUSE;

ADENOCARCINOMA; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; LUNG NEOPLASMS; MICE; MICE, TRANSGENIC; MUTATION; NEOPLASM PROTEINS; SMALL CELL LUNG CARCINOMA; T-LYMPHOCYTES, REGULATORY;

EID: 84996483733     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1600576     Document Type: Article

References (61)

1. Howlader N., A. M. Noone, M. Krapcho, J. Garshell, D. Miller, S. F. Altekruse, C. L. Kosary, M. Yu, J. Ruhl, Z. Tatalovich, et al, eds. SEER Cancer Statistics Review, 1975-2011. National Cancer Institute, Bethesda, MD. Available at: http://seer.cancer.gov/csr/1975-2011.
2. Peifer, M., L. Fernández-Cuesta, M. L. Sos, J. George, D. Seidel, L. H. Kasper, D. Plenker, F. Leenders, R. Sun, T. Zander, et al. 2012. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat. Genet. 44: 1104-1110.
3. Govindan, R., N. Page, D. Morgensztern, W. Read, R. Tierney, A. Vlahiotis, E. L. Spitznagel, and J. Piccirillo. 2006. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveil lance, epidemiologic, and end results database. J. Clin. Oncol. 24: 4539-4544.
4. Ding, L., G. Getz, D. A. Wheeler, E. R. Mardis, M. D. McLellan, K. Cibulskis, C. Sougnez, H. Greulich, D. M. Muzny, M. B. Morgan, et al. 2008. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455: 1069-1075.
5. Cancer Genome Atlas Research Network. 2014. Comprehensive molecular profiling of lung adenocarcinoma. [Published erratum appears in 2014 Nature 514: 262.] Nature 511: 543-550.
6. Pao, W., and J. Chmielecki. 2010. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat. Rev. Cancer 10: 760-774.
7. Morgensztern, D., M. J. Campo, S. E. Dahlberg, R. C. Doebele, E. Garon, D. E. Gerber, S. B. Goldberg, P. S. Hammerman, R. S. Heist, T. Hensing, et al. 2015. Molecularly targeted therapies in non-small-cell lung cancer annual up date 2014. J. Thorac. Oncol. 10(Suppl. 1): S1-S63.
8. Lynch, T. J., I. Bondarenko, A. Luft, P. Serwatowski, F. Barlesi, R. Chacko, M. Sebastian, J. Neal, H. Lu, J. M. Cuillerot, and M. Reck. 2012. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multi-center phase II study. J. Clin. Oncol. 30: 2046-2054.
9. Topalian, S. L., F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith, D. F. McDermott, J. D. Powderly, R. D. Carvajal, J. A. Sosman, M. B. Atkins, et al. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366: 2443-2454.
10. Borghaei, H., L. Paz-Ares, L. Horn, D. R. Spigel, M. Steins, N. E. Ready, L. Q. Chow, E. E. Vokes, E. Felip, E. Holgado, et al. 2015. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373: 1627-1639.
11. Reck, M., I. Bondarenko, A. Luft, P. Serwatowski, F. Barlesi, R. Chacko, M. Sebastian, H. Lu, J. M. Cuillerot, and T. J. Lynch. 2013. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multi-center phase 2 trial. Ann. Oncol. 24: 75-83.
12. Coussens, L. M., and Z. Werb. 2002. Inflammation and cancer. Nature 420: 860-867.
13. Hanahan, D., and L. M. Coussens. 2012. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21: 309-322.
14. Pardoll, D. M. 2012. The blockade of immune checkpoints in cancer immuno-therapy. Nat. Rev. Cancer 12: 252-264.
15. Gabrilovich, D. I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9: 162-174.
16. Helissey, C., S. Champiat, and J. C. Soria. 2015. Immune checkpoint inhibitors in advanced nonsmall cell lung cancer. Curr. Opin. Oncol. 27: 108-117.
17. Coussens, L. M., L. Zitvogel, and A. K. Palucka. 2013. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 339: 286-291.
18. Sparmann, A., and D. Bar-Sagi. 2004. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6: 447-458.
19. Ji, H., A. M. Houghton, T. J. Mariani, S. Perera, C. B. Kim, R. Padera, G. Tonon, K. McNamara, L. A. Marconcini, A. Hezel, et al. 2006. K-ras activation generates an inflammatory response in lung tumors. Oncogene 25: 2105-2112.
20. Wislez, M., N. Fujimoto, J. G. Izzo, A. E. Hanna, D. D. Cody, R. R. Langley, H. Tang, M. D. Burdick, M. Sato, J. D. Minna, et al. 2006. High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras. Cancer Res. 66: 4198-4207.
21. Akbay, E. A., S. Koyama, J. Carretero, A. Altabef, J. H. Tchaicha, C. L. Christensen, O. R. Mikse, A. D. Cherniack, E. M. Beauchamp, T. J. Pugh, et al. 2013. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 3: 1355-1363.
22. Lujambio, A., L. Akkari, J. Simon, D. Grace, D. F. Tschaharganeh, J. E. Bolden, Z. Zhao, V. Thapar, J. A. Joyce, V. Krizhanovsky, and S. W. Lowe. 2013. Non-cell-autonomous tumor suppression by p53. Cell 153: 449-460.
23. Menendez, D., M. Shatz, and M. A. Resnick. 2013. Interactions between the tumor suppressor p53 and immune responses. Curr. Opin. Oncol. 25: 85-92.
24. Politi, K., M. F. Zakowski, P. D. Fan, E. A. Schonfeld, W. Pao, and H. E. Varmus. 2006. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev. 20: 1496-1510.
25. Tichelaar, J. W., W. Lu, and J. A. Whitsett. 2000. Conditional expression of fi-broblast growth factor-7 in the developing and mature lung. J. Biol. Chem. 275: 11858-11864.
26. Jackson, E. L., N. Willis, K. Mercer, R. T. Bronson, D. Crowley, R. Montoya, T. Jacks, and D. A. Tuveson. 2001. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15: 3243-3248.
27. Jonkers, J., R. Meuwissen, H. van der Gulden, H. Peterse, M. van der Valk, and A. Berns. 2001. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat. Genet. 29: 418-425.
28. Eberl, G., S. Marmon, M. J. Sunshine, P. D. Rennert, Y. Choi, and D. R. Littman. 2004. An essential function for the nuclear receptor RORgamma(t) in the generation of fetal lymphoid tissue inducer cells. Nat. Immunol. 5: 64-73.
29. Itohara, S., P. Mombaerts, J. Lafaille, J. Iacomini, A. Nelson, A. R. Clarke, M. L. Hooper, A. Farr, and S. Tonegawa. 1993. T cell receptor delta gene mutant mice: independent generation of alpha beta T cells and programmed rear-rangements of gamma delta TCR genes. Cell 72: 337-348.
30. Marino, S., M. Vooijs, H. van Der Gulden, J. Jonkers, and A. Berns. 2000. In-duction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev. 14: 994-1004.
31. DuPage, M., A. L. Dooley, and T. Jacks. 2009. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat. Protoc. 4: 1064-1072.
32. Houghton, A. M., P. A. Quintero, D. L. Perkins, D. K. Kobayashi, D. G. Kelley, L. A. Marconcini, R. P. Mecham, R. M. Senior, and S. D. Shapiro. 2006. Elastin fragments drive disease progression in a murine model of emphysema. J. Clin. Invest. 116: 753-759.
33. Nikitin, A. Y., A. Alcaraz, M. R. Anver, R. T. Bronson, R. D. Cardiff, D. Dixon, A. E. Fraire, E. W. Gabrielson, W. T. Gunning, D. C. Haines, et al. 2004. Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. Cancer Res. 64: 2307-2316.
34. Jackson, E. L., K. P. Olive, D. A. Tuveson, R. Bronson, D. Crowley, M. Brown, and T. Jacks. 2005. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res. 65: 10280-10288.
35. Culley, F. J. 2009. Natural killer cells in infection and inflammation of the lung. Immunology 128: 151-163.
36. Waldhauer, I., and A. Steinle. 2008. NK cells and cancer immunosurveillance. Oncogene 27: 5932-5943.
37. Groh, V., J. Wu, C. Yee, and T. Spies. 2002. Tumour-derived soluble MIC li-gands impair expression of NKG2D and T-cell activation. Nature 419: 734-738.
38. Wiemann, K., H. W. Mittrücker, U. Feger, S. A. Welte, W. M. Yokoyama, T. Spies, H. G. Rammensee, and A. Steinle. 2005. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo. J. Immunol. 175: 720-729.
39. Esendagli, G., K. Bruderek, T. Goldmann, A. Busche, D. Branscheid, E. Vollmer, and S. Brandau. 2008. Malignant and non-malignant lung tissue areas are differentially populated by natural killer cells and regulatory T cells in non-small cell lung cancer. Lung Cancer 59: 32-40.
40. Mahmoud, S. M., E. C. Paish, D. G. Powe, R. D. Macmillan, M. J. Grainge, A. H. Lee, I. O. Ellis, and A. R. Green. 2011. Tumor-infiltrating CD8+ lympho-cytes predict clinical outcome in breast cancer. J. Clin. Oncol. 29: 1949-1955.
41. Chang, S. H., S. G. Mirabolfathinejad, H. Katta, A. M. Cumpian, L. Gong, M. S. Caetano, S. J. Moghaddam, and C. Dong. 2014. T helper 17 cells play a critical pathogenic role in lung cancer. Proc. Natl. Acad. Sci. USA 111: 5664-5669.
42. Ivanov, I. I., B. S. McKenzie, L. Zhou, C. E. Tadokoro, A. Lepelley, J. J. Lafaille, D. J. Cua, and D. R. Littman. 2006. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126: 1121-1133.
43. Ueda, E., S. Kurebayashi, M. Sakaue, M. Backlund, B. Koller, and A. M. Jetten. 2002. High incidence of T-cell lymphomas in mice deficient in the retinoid-related orphan receptor RORgamma. Cancer Res. 62: 901-909.
44. Meuwissen, R., S. C. Linn, R. I. Linnoila, J. Zevenhoven, W. J. Mooi, and A. Berns. 2003. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell 4: 181-189.
45. Chen, Z., C. M. Fillmore, P. S. Hammerman, C. F. Kim, and K. K. Wong. 2014. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat. Rev. Cancer 14: 535-546.
46. Guo, J. Y., G. Karsli-Uzunbas, R. Mathew, S. C. Aisner, J. J. Kamphorst, A. M. Strohecker, G. Chen, S. Price, W. Lu, X. Teng, et al. 2013. Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes Dev. 27: 1447-1461.
47. Xu, C., C. M. Fillmore, S. Koyama, H. Wu, Y. Zhao, Z. Chen, G. S. Herter-Sprie, E. A. Akbay, J. H. Tchaicha, A. Altabef, et al. 2014. Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell 25: 590-604.
48. Tran, E., M. Ahmadzadeh, Y. C. Lu, A. Gros, S. Turcotte, P. F. Robbins, J. J. Gartner, Z. Zheng, Y. F. Li, S. Ray, et al. 2015. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 350: 1387-1390.
49. Subramanian, J., and R. Govindan. 2007. Lung cancer in never smokers: a re-view. J. Clin. Oncol. 25: 561-570.
50. Govindan, R., L. Ding, M. Griffith, J. Subramanian, N. D. Dees, K. L. Kanchi, C. A. Maher, R. Fulton, L. Fulton, J. Wallis, et al. 2012. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 150: 1121-1134.
51. Ganesan, A. P., M. Johansson, B. Ruffell, A. Yagui-Beltrán, J. Lau, D. M. Jablons, and L. M. Coussens. 2013. Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma. [Published erratum appears in 2013 J. Immunol. 191: 5319.] J. Immunol. 191: 2009-2017.
52. McAllister, F., J. M. Bailey, J. Alsina, C. J. Nirschl, R. Sharma, H. Fan, Y. Rattigan, J. C. Roeser, R. H. Lankapalli, H. Zhang, et al. 2014. Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. Cancer Cell 25: 621-637.
53. Coffelt, S. B., K. Kersten, C. W. Doornebal, J. Weiden, K. Vrijland, C. S. Hau, N. J. Verstegen, M. Ciampricotti, L. J. Hawinkels, J. Jonkers, and K. E. de Visser. 2015. IL-17-producing gd T cells and neutrophils conspire to promote breast cancer metastasis. Nature 522: 345-348.
54. Hannani, D., Y. Ma, T. Yamazaki, J. Déchanet-Merville, G. Kroemer, and L. Zitvogel. 2012. Harnessing gd T cells in anticancer immunotherapy. Trends Immunol. 33: 199-206.
55. Dieu-Nosjean, M. C., M. Antoine, C. Danel, D. Heudes, M. Wislez, V. Poulot, N. Rabbe, L. Laurans, E. Tartour, L. de Chaisemartin, et al. 2008. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J. Clin. Oncol. 26: 4410-4417.
56. Joshi, N. S., E. H. Akama-Garren, Y. Lu, D. Y. Lee, G. P. Chang, A. Li, M. DuPage, T. Tammela, N. R. Kerper, A. F. Farago, et al. 2015. Regulatory T cells in tumor-associated tertiary lymphoid structures suppress anti-tumor T cell responses. Immunity 43: 579-590.
57. van Meerbeeck, J. P., D. A. Fennell, and D. K. De Ruysscher. 2011. Small-cell lung cancer. Lancet 378: 1741-1755.
58. Ott, P. A., M. E. Fernandez, S. Hiret, D.-W. Kim, R. A. Moss, T. Winser, S. Yuan, J. D. Cheng, B. Piperdi, and J. M. Mehnert. 2015. Pembrolizumab (MK-3475) in patients with extensive-stage small cell lung cancer: Preliminary safety and efficacy results from KEYNOTE-028 [abstract]. J. Clin. Oncol. 33: S7502.
59. Garon, E. B., N. A. Rizvi, R. Hui, N. Leighl, A. S. Balmanoukian, J. P. Eder, A. Patnaik, C. Aggarwal, M. Gubens, L. Horn, et al; KEYNOTE-001 Investi-gators. 2015. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372: 2018-2028.
60. Suzuki, K., S. S. Kachala, K. Kadota, R. Shen, Q. Mo, D. G. Beer, V. W. Rusch, W. D. Travis, and P. S. Adusumilli. 2011. Prognostic immune markers in non-small cell lung cancer. Clin. Cancer Res. 17: 5247-5256.
61. Vogelstein, B., N. Papadopoulos, V. E. Velculescu, S. Zhou, L. A. Diaz, Jr., and K. W. Kinzler. 2013. Cancer genome landscapes. Science 339: 1546-1558.